The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 04, 2020

Filed:

Mar. 10, 2016
Applicants:

Beth Israel Deaconess Medical Center, Inc., Boston, MA (US);

Pinteon Therapeutics, Inc., Concord, MA (US);

Inventors:

Kun Ping Lu, Newton, MA (US);

Xiao Zhen Zhou, Newton, MA (US);

Shuo Wei, Chestnut Hill, MA (US);

Lijun Sun, Harvard, MA (US);

Michelle Lynn Hall, Somerville, MA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/196 (2006.01); A61K 45/06 (2006.01); A61K 31/122 (2006.01); A61K 31/4152 (2006.01); A61K 31/4166 (2006.01); A61K 31/4192 (2006.01); A61K 31/4245 (2006.01); A61K 31/452 (2006.01); A61K 31/5375 (2006.01); A61K 31/203 (2006.01); A61K 31/4196 (2006.01);
U.S. Cl.
CPC ...
A61K 31/196 (2013.01); A61K 31/122 (2013.01); A61K 31/203 (2013.01); A61K 31/4152 (2013.01); A61K 31/4166 (2013.01); A61K 31/4192 (2013.01); A61K 31/4196 (2013.01); A61K 31/4245 (2013.01); A61K 31/452 (2013.01); A61K 31/5375 (2013.01); A61K 45/06 (2013.01);
Abstract

The invention features all-trans retinoic acid (ATRA)-related compounds capable of associating with Pin1 and methods of treating a proliferative disorder characterized by elevated Pin1 marker levels, Pin1 degradation, and/or reduced Pin1 Ser71 phosphorylation in a subject by administering an ATRA-related compound. The invention also features methods of treating proliferative disorders, autoimmune diseases, and addiction conditions (e.g., diseases, disorders, and conditions characterized by elevated Pin1 marker levels) by administering an ATRA-related compound in combination with another therapeutic compound.


Find Patent Forward Citations

Loading…